RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,901,070. This represents a 6.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $142,228.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The shares were sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.00, for a total transaction of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total transaction of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00.

RxSight Stock Performance

Shares of RXST opened at $46.40 on Friday. RxSight, Inc. has a 52 week low of $28.88 and a 52 week high of $66.54. The stock’s 50-day moving average price is $48.85 and its 200-day moving average price is $52.44.

Institutional Investors Weigh In On RxSight

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after purchasing an additional 40,500 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in RxSight by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock valued at $3,143,000 after buying an additional 994 shares in the last quarter. California State Teachers Retirement System raised its position in shares of RxSight by 6.8% in the first quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock worth $1,395,000 after acquiring an additional 1,733 shares during the period. RA Capital Management L.P. raised its position in shares of RxSight by 1.1% in the first quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after acquiring an additional 38,540 shares during the period. Finally, CWM LLC boosted its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wells Fargo & Company cut their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, Oppenheimer reduced their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has an average rating of “Buy” and an average target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.